Abstract
Targeting aberrant tyrosine kinase activity may impact clinical outcome in acute myeloid leukemia (AML). We conducted a phase I study of the tyrosine kinase inhibitor midostaurin with bortezomib alone and in combination with chemotherapy in patients with AML. Patients on dose levels 1 and 2 (DL1 & 2) received midostaurin 50 mg bid and escalating doses of bortezomib (1 to 1.3 mg/m2). Patients on DL3 or higher received midostaurin and bortezomib following chemotherapy with mitoxantrone, etoposide, cytarabine (MEC). None of the patients enrolled to DL1 & 2 had dose-limiting toxicities (DLTs) or a clinical response. Among patients enrolled to DL3 or higher, DLTs were peripheral neuropathy, decrease in ejection fraction and diarrhea. A 56.5% CR rate and 82.5% overall response rate (CR + CR with incomplete neutrophil or platelet count recovery) were observed. The midostaurin/bortezomib/MEC combination is active in refractory/relapsed AML, but is associated with expected drug-related toxicities (NCT01174888).
References
Feb 26, 2000·British Journal of Haematology·R FenskiH Serve
Oct 24, 2002·Blood·John C ByrdUNKNOWN Cancer and Leukemia Group B (CALGB 8461)
Sep 13, 2003·Blood·Rui ZhengDonald Small
Nov 8, 2003·Blood·Kazutaka OzekiTomoki Naoe
Dec 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards
May 27, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jorge CortesHagop Kantarjian
Jun 17, 2005·Leukemia·M YanadaT Naoe
Jun 18, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric J FeldmanDavid Scheinberg
Oct 25, 2007·Blood·Rosemary E GaleUNKNOWN Medical Research Council Adult Leukaemia Working Party
Dec 18, 2007·Blood·Shujun LiuGuido Marcucci
Sep 5, 2008·Haematologica·Philippe MoreauJean-Luc Harousseau
Apr 14, 2010·Cancer Cell·Shujun LiuGuido Marcucci
Jan 12, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guido MarcucciHartmut Döhner
Apr 22, 2011·The Lancet Oncology·Philippe MoreauJean-Luc Harousseau
Apr 21, 2012·Blood·Josephine AimiuwuKenneth K Chan
May 9, 2012·Blood·William BlumGuido Marcucci
Nov 7, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eyal C AttarRichard A Larson
Nov 28, 2012·Leukemia·A MimsG Marcucci
Jan 1, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guido MarcucciClara D Bloomfield
Sep 17, 2015·The New England Journal of Medicine·Hartmut DöhnerClara D Bloomfield
Nov 10, 2015·The Lancet Oncology·Christoph RölligUNKNOWN Study Alliance Leukaemia
Citations
Sep 30, 2017·Expert Review of Clinical Pharmacology·Sabine KayserRichard F Schlenk
Oct 21, 2017·Therapeutic Advances in Hematology·Molly M GalloglyBrenda W Cooper
Oct 27, 2017·Cancer Metastasis Reviews·Jacqueline CloosGerrit Jansen
Oct 5, 2017·Pharmacotherapy·Lindsay C Stansfield, Daniel A Pollyea
Jun 15, 2017·Future Oncology·Mrinal M Patnaik
Dec 7, 2018·Hematology·Laura C Michaelis
Jan 18, 2019·Leukemia & Lymphoma·Jan Philipp BewersdorfAmer M Zeidan
Jun 25, 2019·Expert Review of Hematology·Eran Tallis, Gautam Borthakur
Nov 7, 2019·Cancers·R Willow Hynes-SmithShannon M Buckley
Jul 12, 2019·Cancer Gene Therapy·Longzhen CuiLin Fu
Oct 30, 2019·Mini Reviews in Medicinal Chemistry·Xu HuDahong Li
Nov 22, 2016·Aging·Ivan PetrovAnton Buzdin
Sep 19, 2019·Biomarker Research·Juanjuan ZhaoDelong Liu
Dec 6, 2018·Journal of Hematology & Oncology·Mei WuXiongpeng Zhu
Aug 10, 2018·JCI Insight·Irum KhanAndrei L Gartel
Apr 18, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Anjali S AdvaniMikkael A Sekeres
Jan 12, 2021·Frontiers in Oncology·Vanessa E Kennedy, Catherine C Smith
Mar 2, 2021·Genomics·Siyao DongYan Xu
Mar 16, 2021·Journal of Medicinal Chemistry·Zhijie WangShuai Lu
Oct 15, 2021·BMC Cancer·Ying ZhangChanglin Li